EAP for convalescent plasma no longer enrolling; the FDA authorized emergency use.

See "EAP to EUA transition" box for physician instructions

Learn more

EAP to EUA transition

  • Note: System outage. The REDCap system used for EAP program forms will be unavailable Friday, Oct. 9, 2020, from 12:10-1:10 a.m., Central time.
  • On Sept. 23, 2020, the FDA posted a document summarizing updated evidence to support the emergency use of COVID-19 Convalescent Plasma. The agency continues to review the circumstances and appropriateness of the authorization for emergency use. To make this information accessible to the public, the document presents FDA’s review in relatively plain language.
  • Enrollment and the ability to order plasma in the Mayo-led EAP have ended.
  • Physicians who need to order convalescent plasma for patients should do so using the FDA's emergency use authorization (EUA).
  • Physicians who have patients currently enrolled, consented and plasma ordered prior to September 1, 2020, in the expanded access program need to complete the required paperwork through the program physician's workflow.
  • Completing all forms is required as part of the agreement to participate in the program, statement of investigator commitments, and in compliance with federal regulations.
  • Read more about the EAP to EUA transition and the differences between the two.

Historical EAP program participation

  • Sites
  • Physicians
  • Patients
  • Infused